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Abstract
Metabolomics, the youngest of the major omics technologies, is supported by an
active community of researchers and infrastructure developers across Europe. To
coordinate and focus efforts around infrastructure building for metabolomics within
Europe, a workshop on the “Future of metabolomics in ELIXIR” was organised at
Frankfurt Airport in Germany. This one-day strategic workshop involved
representatives of ELIXIR Nodes, members of the PhenoMeNal consortium
developing an e-infrastructure that supports workflow-based metabolomics analysis
pipelines, and experts from the international metabolomics community. The workshop
established  as the critical area, where a maximal impact ofmetabolite identification
computational metabolomics and data management on other fields could be achieved.
In particular, the existing four ELIXIR Use Cases, where the metabolomics
community - both industry and academia - would benefit most, and which could be
exhaustively mapped onto the current five ELIXIR Platforms were discussed. This
opinion article is a call for support for a new ELIXIR metabolomics Use Case, which
aligns with and complements the existing and planned ELIXIR Platforms and Use
Cases.
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Introduction
Metabolomics aims to provide novel insights into the biochem-
istry of organisms by characterising the presence and concentra-
tions of low molecular weight compounds from biological samples. 
It measures both endogenous (produced within an organism) and 
exogenous (those introduced from the environment including 
food components and drugs) metabolites. The primary analytical 
tools for such high-throughput data collection are mass spec-
trometry (MS), often preceded by chromatographic or electro-
phoretic separation technologies, and nuclear magnetic resonance 
spectroscopy (NMR). These technologies produce relatively 
large and complex data sets that require bioinformaticians, 
cheminformaticians, biostatisticians and computer scientists to 
develop and apply a wide range of algorithms, software tools, 
repositories and computational resources to process, analyse, report 
and store the data and metadata.
The field celebrated its coming of age in 20161 and progressed 
primarily through developments in analytical and computational 
tools, from which biomedical discoveries followed. As shown in 
Figure 1, the term ‘metabolomics’ is still gaining momentum 
and the global market for metabolomics was valued at $5.9 
billion in 2014 and was expected to reach $12.5 billion by 2020, 
with a compound annual growth rate (CAGR) of 13.0% (https://
goo.gl/yXTiJD). The future is bright for the application of 
metabolomics in academic and industrial laboratories, scien-
tific instrument companies, government laboratories and contract 
research organisations. Yet, several challenges remain. Discussions 
amongst both independent metabolomics experts, and those 
within ELIXIR (http://elixir-europe.org/), culminated at the recent 
workshop the “Future of metabolomics in ELIXIR”. This opin-
ion article summarises the interactions in the workshop and its 
outcomes.
ELIXIR coordinates bioinformatics resources across its mem-
ber states and help researchers to find, analyse, and exchange 
biological data. It is a distributed infrastructure with a single 
Hub based in Hinxton, United Kingdom, and an increasing 
number of Nodes located throughout Europe. As of July 2017, 
ELIXIR has 20 national Nodes, with European Bioinformatics 
Institute (EMBL-EBI; co-located with the Hub), working as a 
separate Node.
Workshop “The future of metabolomics in ELIXIR”
The workshop was organised at the Airport Conference Center on 
April 25th 2017 in Frankfurt (Germany). The invitation to the 
workshop was widely advertised through the newsletter of the 
Metabolomics Society (http://metabolomicssociety.org), the 
PhenoMeNal (Phenome and Metabolome aNalysis) project 
website (http://phenomenal-h2020.eu) and ELIXIR dissemi-
nation channels, including ELIXIR Technical Coordinators, 
Heads of Node mailing lists and the ELIXIR newsletter (https:// 
goo.gl/KVUb8y). The invitation was also extended to the part-
ners of the MetaStar consortium (http://meta-star.eu, the H2020 
Metabolomics Starting Community), and interested members 
of the metabolomics community.
Figure 1. Annual count of mentions of the term ‘metabolomics’ (and related terms) in the literature over time, annotated with important 
milestones in data sharing and standards in metabolomics. Source: Data from Google Scholar.
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The workshop included 35 participants from across 10 countries, 
representing the ELIXIR Nodes including Belgium, EMBL-EBI, 
Estonia, France, Germany, Greece, Italy, Luxembourg, The Neth-
erlands, Spain, The United Kingdom, and the ELIXIR hub. The 
objective of the meeting was to identify the principal challenges 
within this field and prioritise actions, in particular those within 
the scope and mission of ELIXIR. The workshop showcased flash 
presentations on the national metabolomics activities in the par-
ticipating Nodes and ideas and requirements for future develop-
ments of ELIXIR metabolomics activities. An overview of ELIXIR 
Use Cases and Platforms was also presented by Rafael Jiménez 
(ELIXIR Chief Technology Officer), representing the ELIXIR Hub. 
The presentations were followed by discussions on the needs and 
challenges present in the metabolomics community. The following 
challenges were identified:
1.   Minimum information standards and early data capture
2.   Global spectral databases
3.   Tools and standards registries
4.   Compound identifier mapping
5.   Omics data integration
6.   Metabolite identification
These challenges are described in more detail in the following 
paragraphs.
Identification of challenges
Minimum information standards and early data capture
In 2007 the Metabolomics Standards Initiative (MSI)2,3 published a 
set of seminal papers with recommendations on minimal reporting 
standards for a number of aspects in metabolomics, summarized 
in 4. This work built on earlier efforts by the Standard Metabolic 
Reporting Structure initiative5 and the Architecture for Metabo-
lomics consortium (ArMet)6. Although critical, the MSI work 
served only as a starting point. Since then, several initiatives have 
been set up to address elements of standardisation, particularly on 
data standards, building on the work of the MSI. The COSMOS 
project (COordination Of Standards In MetabOlomicS, http://www.
cosmos-fp7.eu)7, coordinated data standards efforts amongst data-
base providers, ontologists, software engineers and instrument 
vendors working towards open access data standardization and 
agreements. A Metabolomics Society Data Standards Task Group 
was subsequently established to foster and coordinate efforts in 
enabling efficient storage, compression, terminological annotation, 
exchange and verification of information within metabolomics data-
sets. However, no significant and coordinated effort has since been 
attempted on minimum reporting itself: there is now widespread 
agreement that the early work of the MSI needs to be taken up in a 
new initiative, linked with related activities such as the HUPO-PSI 
(http://www.psidev.info), and be ‘completed’. Indeed, the lack of 
standardised and validated reporting in the field of metabolomics 
has now become a significant hindrance for data reuse and the 
translation of this technology into regulated areas of science. For 
example, one conclusion from a European workshop on regulatory 
toxicology stated that “there are a number of R&D needs, including 
a database to support metabolomics, standardisation, validation and 
reporting formats” (https://goo.gl/EiuTfM), and progress is now 
underway8 (https://goo.gl/HapKhz). The multiple task groups of the 
international Metabolomics Society have objectives to educate and 
reform reporting standards including the Metabolite identification 
and QA/QC task groups.
Global spectral databases
In contrast to genomics, there is a lack of metabolite databases with 
sufficient depth and breadth covering entire metabolomes. There 
are no databases capable of providing a near comprehensive snap-
shot of the molecular diversity available.
While a number of databases around the globe store and serve 
spectral data, there is no open and comprehensive resource targeted 
at the needs of metabolomics. The public repository MassBank 
(http://www.massbank.jp/en/database.html), which stores mass 
spectral data, is actively developed and used by members of the 
metabolomics community. However, it is designed to hold only 
reference spectra and not experimental raw data. For NMR, a few 
and sparsely populated repositories provide raw data for individual 
metabolites, such as the metabolomics collection in BioMagRes-
Bank (http://www.bmrb.wisc.edu/www/resources.shtml)9.
Efficient metabolite identification requires several fundamental 
resources and developments, which mandate concerted efforts 
across research groups and countries in Europe and worldwide. In 
the field, two main types of resources exist:
1.    Databases of measurements: Resources such as the Human 
Metabolome Database (HMDB, http://www.hmdb.ca)10, 
and the Yeast Metabolome Database (YMDB, http://
www.ymdb.ca)10,11 store MS and NMR measurements of 
known compounds but also collect and curate published 
results with the aim to establish specific organism reference 
metabolomes.
2.    Genome-based metabolic reconstruction databases: These 
databases are built based on genome annotation, mostly of 
enzymes and their association to known reactions, and thus 
may not cover the entire metabolome since some genes that 
are enzymes have no enzymatic function associated and 
some functions may not yet be known. Normally they do 
not include spectral data, but they are valuable in associ-
ating expected metabolites to defined species. Examples 
include KEGG12, BioCyc13 and Recon14, which is a human 
genome-scale metabolic reconstruction.
Open-access metabolite databases such as the commercial 
Reaxys database (https://www.reaxys.com), Chemical Entities of 
Biological Interest (ChEBI, https://www.ebi.ac.uk/chebi/15), and 
KNApSAcK16 contain data on species-metabolite associations, 
besides those mentioned in the Genome-based metabolic recon-
struction databases category.
One important consideration in this arena is that different confi-
dence levels can be associated with structural identification of 
metabolites17, and standardized annotation schemes for such evi-
dence descriptions are currently emerging18. The highest confidence 
level can only be observed when instrumental data for an authentic 
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chemical standard is matched to the data for the biological samples. 
However, authentic chemical standards are not available for many 
metabolites and therefore bioinformatics and chemoinformatics, 
including through ELIXIR supported resources, are essential to 
solve this community-wide hurdle.
Recently, as one strategy to accelerate the identification of metab-
olites in biological systems, a task group within the International 
Metabolomics Society has promoted the idea of characterising 
model organism metabolomes19,20. The philosophy of this task 
group is to leverage upon the critical mass of knowledge and activ-
ity that already exists for model organisms, linking to these other 
efforts and exploiting resources such as sequenced genomes to pre-
dict metabolism (as targets for experimental investigation) using 
genome-wide metabolic reconstructions or metabolic pathway 
databases KEGG12, BioCyc13, and WikiPathways21. The task group 
has set a grand challenge for the community, to identify and map all 
metabolites onto metabolic pathways, to develop quantitative meta-
bolic models for model organisms, and to relate organism meta-
bolic pathways within the context of evolutionary metabolomics22. 
To assist the experimental community in generating and gathering 
high-quality metabolomics data about biological models, an Imple-
mentation Study proposal called “MetabolHomes” has been sub-
mitted to ELIXIR as part of the present Metabolomics Use Case, 
which aims at providing users with a generic data model and the 
associated software tools for data management, visualisation, and 
annotation.
Tools and standards registries
Since its inception, the Metabolomics community has developed 
a plethora of computational tools for data analysis (https://goo.
gl/Crf2Ye), as well as data and minimum information standards 
(https://goo.gl/gouSQY). There is a general feeling that it is dif-
ficult for the average researcher to navigate both areas.
The suggestion here was to contribute to and improve long-term 
supported registries of tools and standards that help researchers 
decide which mature, well-tested tools and standards to use for 
which purpose. There is a need for more metabolomics tools to be 
appropriately included in ELIXIR’s Tools and Data Service Regis-
try (currently, there are 56 tools/DBs tagged with ‘metabolomics’ 
in the registry).
Compound identifier mapping
In order to interpret the biological relevance of measured metabo-
lites, their structures must be mapped to existing knowledge i.e., 
to pathways using a multi-omics data integration approach. Many 
metabolomics experiments measure a metabolite and characterise 
the structure with a retention time, one or more m/z values, or an 
NMR spectrum. Sometimes this characterisation can be linked to 
an identity of a specific chemical compound but often it can be only 
linked to a compound class. However, the tagged identity is com-
monly different from what is found in metabolism knowledge bases. 
In fact, different knowledge bases may have different focuses and 
representations of compounds. For example, one knowledge base 
may focus on the biological role of the metabolite, while another 
contains precise representations of the metabolites chemical struc-
ture and properties. Furthermore, knowledge bases are typically 
either too broad or too narrow in scope, and frequently not interop-
erable. Chemical structure mapping is therefore an important aspect 
to ensure interoperability between experimental and biochemical 
resources.
No generic solution currently exists, and people use either map-
ping based on expert knowledge23,24 or on equivalence based on the 
chemical structure, e.g. with the InChI string or key25,26. However, 
neither approach is well-suited for solving the issues around ambi-
guities in the characterisations of both the experimental side and the 
knowledge side. Theoretical solutions exist for linking these facts, 
such as scientific lenses27, but these need to be extended to service 
the metabolomics research field.
In addition, pattern recognition analysis, such as Pavlidis template 
matching (Pavlidis and Noble, 2001) could further assist in identi-
fying the biological role of the metabolite in the metabolic network 
and add to its chemical identification. Pavlidis template matching 
clusters a metabolite based on its concentration pattern with other 
metabolites of known identity or class in an experiment (or multiple 
experiments that are combined in a meta-analysis).
Omics data integration
Metabolites function as both reactants and products of metabolic 
reactions. However, they also serve as regulatory molecules of 
proteins, affecting the structure and control of protein interac-
tion and gene regulatory networks. This dual role of metabolites 
ensures that metabolomics is an integral aspect of systems biology 
research. 
There is a great need for standardised integrated multi-omic analy-
ses for the comprehensive understanding of the cellular physiology 
with significant applications in biomedicine and all the spectrum 
of biotechnology. Thus, establishing standardized protocols of 
multi-omic (i.e. metabolomic, transcriptomic, proteomic, and 
interactomic) data representation, integration, visualization and 
interpretation is of great importance. Currently, metabolomics data 
can be integratively visualised with transcriptomics data. However, 
there is a lack of integrated omic databases for most model systems 
and it is not self-explanatory how a genomicist/proteomicist could 
integrate his/her data with metabolomics data that refers to the 
same biological system and vice versa. Additionally, there is a lack 
of harmonization of the experimental design, sample collection, 
handling and quenching protocols of metabolomics monitoring, 
which further increases the challenge of integrated omics analysis. 
The ELIXIR group proposed that these issues of integrated omic 
analysis and the standardization of metabolomic data interpretation 
in this context, could be tested and explored via comparison and 
analysis of a controllable reference biological system, such as a 
well-characterized human cell line. 
Genome scale metabolic networks and metabolic pathway databases 
contain information both on metabolites and their reactions with 
corresponding genes and proteins. Thus, these networks provide 
valuable context for simultaneous interpretation of metabolomics 
data and other omics data. However, mapping metabolites in these 
databases is a heavy workload (see above), since most of databases 
use specific identifiers for small molecules, where ideally chemical 
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structure mapping should be applied. This is a particularly striking 
issue with genome-scale metabolic models, as these were initially 
built for constraint-based computational studies (flux balance anal-
ysis and related), where the chemical structure of small molecules 
plays no role. Because of this, no effort was put into those models 
to use proper small molecules identifiers, and instead only short and 
ambiguous names were used for small molecules, making mappings 
very difficult. Hence, omics data integration was not considered at 
all in their design and most of these databases (available in SBML 
format) do not provide standard metabolite identifiers. The MSI 
recommends a number of identifiers e.g. HDMB ID, ChEBI ID, 
CAS ID, and IUPAC Name, but only InChI and InChIKey encode 
the chemical structure themselves.
Recently, the Recon human genome-scale metabolic reconstruction 
network was enriched to incorporate InChIs, but more compre-
hensive chemical structure mapping is needed to capture all of the 
biological details. However, still most of the existing genome-scale 
metabolic reconstructions available for other organisms have not 
been enriched at this level. There is thus a strong need to coordinate 
with this community in order to facilitate the integration of metabo-
lomics data in the context of these networks.
The problem of integrating metabolomics data into genome-scale 
metabolic models does not end in the community being able to 
map small molecules available there to proper identifiers, it only 
begins there. Classically, most established analysis methods used 
to simulate those models (Constraint-based analysis methods) are 
not prepared to use metabolite concentrations/abundances, as they 
only aim to balance incoming and outgoing reaction fluxes on each 
metabolite. So the use of metabolomics data in the context of these 
networks will present new challenges to the modelling community 
as well.
Metabolite identification
Unlike genomics, the analytical Platforms used in metabolomics 
and lipidomics will not per se deliver a molecular identity, i.e. a 
specific chemical compound, but only the spectral characteristics. 
In untargeted metabolomics, metabolite identification remains the 
main bottleneck in data analysis and interpretation28. The typical 
output is a spectrum containing (a large number of) features, which 
are characterised in NMR by the location and intensity of signals on 
a frequency axis, and in MS by m/z values (and possible additional 
information like retention time if coupled to a chromatographic sys-
tem or drift times if coupled to ion mobility). In targeted metabo-
lomics, data acquisition instrument parameters are tuned to detect (a 
list of) target compounds, thus making it possible to deliver tables 
of metabolite abundances, ideally with absolute quantification, 
for downstream biochemical interpretation. In recent years, both 
approaches have been improved towards each other, resulting in 
widely targeted metabolomics, covering hundreds of compounds29.
Furthermore, computational tools for untargeted metabolomics 
methods have improved their ability to deliver metabolite annota-
tion, albeit with varying levels of certainty30. Concerted efforts in 
ELIXIR and the community can facilitate to improve the current 
situation, by removing the burden on developers to manually con-
nect different tools into pipelines, and on experimentalists, by pro-
viding the tools and resources that give access to the knowledge 
required for biochemical interpretation of the data.
Metabolomics Use Case in ELIXIR
After extensive discussions during the workshop, metabolite identi-
fication was identified by popular vote as the one area where:
A.    A maximal impact of computational metabolomics and 
metabolomics data management could be aligned with 
other fields, in particular with the existing four ELIXIR Use 
Cases (https://www.elixir-europe.org/use-cases).
B.    Metabolomics community would benefit most
C.    Can be exhaustively mapped onto the existing five ELIXIR 
Platforms.
ELIXIR technical activities
ELIXIR technical activities are performed by ELIXIR Nodes and 
supported by the Hub. The Nodes run bioinformatics resources and 
services focusing on national priorities and contributing to a harmo-
nised strategy across Europe. At the national level, an ELIXIR Node 
consists of research institutes within a member country, building 
on their national strengths. At the European level, ELIXIR’s activi-
ties are structured around Platforms and Use Cases, which bring 
resources and expertise together from both the ELIXIR Nodes and 
the basic unit of operation within ELIXIR. The ELIXIR Platforms 
are responsible for the implementation of the ELIXIR Scientific 
Programme, which is organised into five key areas: Data, Tools, 
Compute, Interoperability and Training.
The four Use Cases that currently represent four scientific com-
munities are: Human Data, Rare Diseases, Marine Metagenomics 
and Plant Sciences. The Use Cases drive the work of the ELIXIR 
Platforms by describing their bioinformatics requirements. A close 
collaboration between the ELIXIR Use Cases and Platforms safe-
guards services developed by the ELIXIR Platforms would be fit 
for purpose.
Metabolomics activities are well represented within Europe and 
ELIXIR nodes. Following the establishment of national efforts such 
as the French MetaboHUB31 and the Netherlands Metabolomic 
Centre, transnational efforts such as the FP7 coordination action 
COSMOS and the H2020 e-infrastructure PhenoMeNal followed. 
ELIXIR Greece has included a computational metabolomics and 
protein interactomics Use Case in the strategic planning for the 
national infrastructure. An ELIXIR Use Case on Metabolomics can 
have a positive impact on the community, strengthening collabo-
ration and delivering a more harmonised strategy amongst service 
providers. Metabolomics aligns with the ELIXIR Platforms and 
Use Cases as well as other Omics themes represented and proposed 
in ELIXIR like Genomics and Proteomics. Though “metabolite 
identification” is not the only activity of interest within the ELIXIR 
Nodes, we proposed this Use Case as a starting point of common 
interest to catalyze the collaboration amongst ELIXIR Nodes and 
ELIXIR Platforms.
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Alignment with ELIXIR Platforms
The Metabolomics community in ELIXIR has vast expertise in the 
five areas represented by ELIXIR Platforms (Data, Tools, Interop-
erability, Compute and Training). Next, we summarise the current 
Platforms’ priorities, how the selected metabolomics Use Case 
aligns with the Platforms and a general alignment of metabolomics 
activities within Europe.
1. Data Platform
The Data Platform focuses on sustaining long term Europe’s life 
science data infrastructure by working on guidelines and indica-
tors to improve data resources impact and long-term sustainability. 
Additionally, this platform aims to improve links between curated 
and non curated data resources and literature.
On the data side, metabolite identification requires a) the availabil-
ity of high-quality curated resources for compound de-replication 
(the process of finding known chemical compounds in databases 
based on their spectroscopic and chromatographic fingerprints) as 
well as b) the establishment of workflows to push data on newly 
identified metabolites into the existing repositories. For a), the ref-
erence layer of the MetaboLights32 database plays a crucial role and 
needs to be extended. The reference layer holds information about 
individual metabolites, their chemistry, their spectral data (MS, 
NMR), as well as their role in pathways and biological systems. 
New metabolites identified in studies deposited into MetaboLights 
(http://www.ebi.ac.uk/metabolights/) are being curated by the 
MetaboLights team and added to the reference layer. In particu-
lar, characterization of the metabolome of biological models (e.g. 
organisms, tissues, biofluids, cell lines) is of major importance for 
the understanding of biochemical mechanisms, for the exploration 
of phenotype diversity and for the identification of new biomarkers. 
Due to the variety and the complexity of each biological system, 
gathering and curating knowledge about metabolomes can be best 
achieved by expert communities. In genomics, the GMOD project 
(http://gmod.org/wiki/Main_Page) provides biological research 
communities with open-source software components for annotat-
ing and managing data about model organisms. Developing such 
data models and software tools in metabolomics to gather, analyse, 
and curate data will therefore be critical to produce high-quality 
knowledge about model metabolomes. The curated data (spectra, 
compounds, networks) and workflows will be of high value as input 
for the corresponding reference repositories and e-infrastructures 
(MetaboLights, ChEBI, MetExplore, Workflow4Metabolomics, 
PhenoMeNal).
Europe is a major provider of massive and high-quality metabo-
lomics data. Large endeavors such as the MRC-NIHR National 
Phenome Centre (http://www.imperial.ac.uk/phenome-centre), 
Phenome Centre Birmingham (http://www.birmingham.ac.uk/
research/activity/phenome-centre/index.aspx), the Netherlands 
Metabolomics Center (http://www.metabolomicscentre.nl), and 
the French MetaboHUB (http://www.metabohub.fr/home.html31) 
infrastructure are producing data in key scientific and socio- 
economic areas, including the ELIXIR Use Cases (https://www. 
elixir-europe.org/use-cases). Valorisation of this wealth of data 
requires annotation practices to be refined and new software 
tools to be developed to assist chemists in formatting, validating, 
referencing, and curating their annotations. All parties mentioned 
above have been engaging in the European GO-FAIR (https:// 
www.dtls.nl/go-fair/) initiative through their participation in Phe-
noMeNal, which has recently been co-organising the launch of 
a hub for FAIR metabolomics data in goFAIR. The FAIR data 
movement has gained considerable momentum in Europe, where 
FAIR33 stands for data being Findable, Accessible, Interoperable 
and Reusable.
2. Tools Platform
The Tools Platform drives access and exploitation of bioinformat-
ics research software by working closely with services and con-
nectors. Additionally, this Platform aims to facilitate the discovery, 
benchmarking and interoperability of bioinformatics software by 
focusing on software development, best practices and on strategy 
for workflows and software containers.
Workflow management e-infrastructures such as Workflow4Me-
tabolomics (http://workflow4metabolomics.org/)34,35, PhenoMeNal, 
and Galaxy-M36 are key European resources built on the Galaxy 
environment37 that simultaneously address the two challenges 
of 1) high-performance, user-friendly, modular, and reproduc-
ible data analysis (needed by the experimental community), and 
2) collaborative contributions from the bioinformatics commu-
nity. Comprehensive workflows for preprocessing, statistical 
analysis, and annotation of data from liquid chromatography - MS 
(LC-MS), direct infusion MS (DIMS), gas chromatography - MS 
(GC-MS), and NMR technologies can be created, tailored, run, 
saved, shared, and publicly referenced with digital object identifiers 
(http://workflow4metabolomics.org/referenced_W4M_histories). 
A recent questionnaire has shown a need to further develop 
such tools and workflows, as part Galaxy, that are well supported 
through community-based training, to further improve the stand-
ardisation and automation of data processing and analysis38.
Standardization of compound annotation is critical for such Plat-
forms i) to enable individual modules to communicate between 
each other and with external resources (e.g., repositories for raw 
data, mass spectra, compounds and metabolic networks) and ii) to 
deliver useful and FAIR data to the end-user. Conversely, new mod-
ules can be developed to integrate and harmonize annotations from 
complementary resources.
3. Interoperability Platform
The Interoperability Platform provides support to the discovery, 
integration and analysis of biological data organised in projects, 
centred around persistent identifiers, metadata and data standards 
for exchange and storage formats in addition to controlled vocabu-
laries and linked data. This Platform facilitates work on the descrip-
tion of interoperability services and organises specialised BYOD 
(Bring Your Own Data) workshops with the aim to improve the 
FAIRness of data resources.
Experimental metabolomics data must be interoperable in order to 
facilitate integration with existing knowledge bases and other omics 
data. Interoperability can be realized by community accepted data 
standards and ontological molecule representations. Persistent 
Identifiers for metabolites are a central need here, as is the more 
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general chemical structure mapping problem (see above). The 
latter is a need that this metabolomics Use Case has in common with 
the Human Data, Rare Diseases, Marine Metagenomics and Plant 
Science Use Cases. The interoperability needs for metabolomics, 
however, extends beyond chemical structures: more standardized 
interoperability of experimental data, such as NMR spectra, is also 
required. Introduction of the SPLASH39 for NMR would benefit the 
other Use Cases too.
4. Compute Platform
The Compute Platform is devoted to the compute, transfer, storage, 
authentication and authorization related to biological data relying on 
services provided by ELIXIR Nodes and other e-infrastructures.
With PhenoMeNal, Europe now has at least one major initiative to 
support computing with large-scale metabolomics data. The Phe-
noMeNal e-infrastructure enables researchers to deploy and test 
metabolomics workflows in public clouds (Amazon EC2, Google 
Compute Platform) or local, in-house OpenStack environments 
in cases where sensitive data cannot leave the institution. It also 
provides a number of commonly used workflows for metabolomics 
that include the eventual identification of metabolites in metabo-
lomics experiments and the mapping onto biological pathways. 
PhenoMeNal unites major metabolomics laboratories across Europe 
and forms an essential component for our next steps to launch a 
European infrastructure for metabolomics service laboratories.
5. Training Platform
This Platform aims to increase the professional skills for manag-
ing and exploiting data. The training activities focus on researchers, 
trainers and service providers, but also include e-learning, the dis-
covery of training materials and measuring the impact of training.
The need for further development of training programmes in 
metabolomics across Europe is well recognised, including train-
ing in metabolite identification40. Over the last few years multiple 
training courses have been established, somewhat ad hoc, both in 
relatively large training centres as well as individual laboratories 
that specialise in a particular aspect of metabolomics. Currently, 
there is a critical need to improve the coordination between these 
training courses and initiatives, and to ensure that all stakeholders 
across Europe and beyond (e.g. NIH training centres in USA and 
Metabolomics Australia) are able to readily access courses, from 
introductory to advanced, including online and face to face. This is 
one of the objectives of the newly formed European Metabolomics 
Training Coordination Group (EmTraG, http://www.emtrag.eu), 
led initially by a team in ELIXIR-UK with support from several 
other ELIXIR Nodes and the ELIXIR Training Platform.
Specifically in the context of metabolite identification, several 
introductory training courses teach the basics of metabolite annota-
tion and identification. In addition the Birmingham Metabolomics 
Training Centre (BMTC), an ELIXIR-UK training resource, runs 
a course “Metabolite identification with the Q Exactive and LTQ 
Orbitrap” in partnership with Thermo Scientific. Formalising a 
Metabolomics Use Case within ELIXIR could enable the expan-
sion of the delivery of such courses, for example through the 
EmTraG network. Training partnerships with instrument vendors 
can be extremely valuable, increasing the quality of the training 
material and facilities, as also has been achieved by Waters Corpo-
ration partnering with the Imperial International Phenome Training 
Centre and the BMTC.
Training in metabolite identification requires materials and case 
studies related to both data acquisition and bioinformatic analysis 
of the acquired data and a multi-disciplinary training team of ana-
lytical chemists and bioinformaticians to deliver courses. The pro-
vision of courses currently focuses on hands-on training at training 
centres, as described above at the BMTC, and which typically can 
train 6–12 scientists per course. However, in the growing discipline 
of metabolomics, there is a requirement to provide training to larger 
numbers that is only achievable through online training resources. 
The matching of trainee learning objectives to the type of course 
provided is key and recent examples of online courses have dem-
onstrated their power in delivering Massive Open Online Courses 
(MOOCs) or more specialised Small Private Online Courses 
(SPOCs). At BMTC, the introductory course on metabolomics 
MOOC has been used by greater than 3000 active learners and the 
first SPOC focussed on data processing and analysis in metabo-
lomics was completed by more than 50 people. However, courses 
for greater levels of hands-on training in the laboratory are focused 
on training in the laboratory; through the use of video media we can 
envisage some courses operating via online resources.
For training purposes, the Galaxy framework has also shown that 
it could be an efficient Platform to explain tools, parameters and 
workflows to life scientists without any skills in scripting (R, Bash, 
Python). The trainees can focus on their scientific questions regard-
less the technical aspects and programming language barrier. Since 
2014, the Workflow4Metabolomics group (ELIXIR-FR, Metabo-
HUB) have conducted three sessions of one week based on their 
Galaxy instance. For those who wish to use the command line after 
the training session, the bridge is easy since the parameters within 
Galaxy are mapped exactly on the native software.
ELIXIR training modules can be classified into three types of 
trainers:
1) Life Scientist (TrR): “Bring Your Own Data” training addressed 
to the experimentental community optimally promote good prac-
tices for using software and critically interpreting the results, and 
provide feedback about specific training needs. As an example, dur-
ing the Workflow4Experimenters (ELIXIR-FR, MetaboHUB) one-
week courses (W4E) (http://workflow4metabolomics.org/events), 
participants learn to analyze their own MS or NMR datasets by 
using the Workflow4Metabolomics Platform. Morning sessions 
are dedicated to methodology and tools and afternoon sessions are 
devoted to tutoring. Such training offers unique opportunities to 
discuss the designs, methods, and tools for comprehensive and rig-
orous data preprocessing, statistical analysis, and annotation.
2) Communities of Developers (TrD): to enrich the tools 
and compute Platforms based on good practices guidance. As an 
example, the ELIXIR-EXCELERATE and IFB (ELIXIR-FR) 
European Galaxy Developer Workshop (EGDW, https://www.
elixir-europe.org/events/elixir-excelerate-and-ifb-european- 
galaxy-developer-workshop), hosted in Strasbourg, aimed to teach 
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the best-practices about the tool integration and advanced features 
like the Galaxy API, visualisation and administration (high per-
formance computing (HPC), Docker).
3) Trainers expert (TrT): Train the trainers program with the best 
strategies in Learning principles and didactic strategies for deliver-
ing bioinformatics in the most effective way
Alignment with ELIXIR Use Cases
The ELIXIR Platforms are currently complemented by four Use 
Cases across four scientific communities:
1.    The Human Data Use Case for long-term strategies for man-
aging and accessing sensitive human data.
2.    The Rare Disease Use Case for development of new thera-
pies for rare diseases.
3.    The Marine Metagenomics Use Case works towards a sus-
tainable metagenomics infrastructure to support research 
and innovation in the marine domain.
4.    Plant Science Use Case for infrastructure development for 
genotype-phenotype analysis of crop and tree species.
As one of the core omics technologies, metabolomics forms an 
important component in all of the science-driven Use Cases estab-
lished so far in ELIXIR. In particular, for the human data Use Case, 
the PhenoMeNal e-infrastructure is very relevant as is working 
to develop cloud-based resources for computing with big clinical 
metabolomics data. Significant synergies between the privacy and 
ethics work package in PhenoMeNal and the parties working on the 
human data Use Case are obvious.
As one of the best established molecular phenotypes, metabolomics 
is already widely used for the genotype-phenotype analysis of crops 
and in tree species, providing an immediate interplay with the Plant 
Science Use Case. A rich corpus of work exists on the metabo-
lomics of marine organisms where communities of, for example, 
marine sponges and marine microorganisms produce pharmaco-
logically active polyketides with diverse chemical structures, which 
are investigated based on genomic and macroeconomic data of 
these communities.
In all those application scenarios, the mapping of spectral features 
in metabolomics data to identified chemical compounds (metabo-
lites) and thereby to molecular pathways is crucial for the under-
standing of the biochemistry underlying the Use Case in question.
Following the formation of national infrastructures for 
metabolomics, for example with the French infrastructure in 
Metabolomics and Fluxomics MetaboHUB and the Netherlands 
Metabolomics Centre Foundation (NMC), the COSMOS initiative7 
for the coordination of standards in metabolomics provided the 
first coordination action between all relevant efforts in metabo-
lomics in Europe. Leading to the establishment of the worldwide 
metabolomeXchange network, COSMOS paved the way for Phe-
noMeNal. As a core organiser of the launch of the node for FAIR 
data33 in metabolomics as part of the goFAIR initiative, the Phe-
noMeNal consortium made another necessary step to establish 
itself as an authority for metabolomics data ELIXIR Greece has 
included a computational metabolomics and protein interactom-
ics Use Case, including the formation of standardized integrated 
metabolomic and proteomic databases and the evolvement of 
tools for combined metabolic and protein network analysis, in the 
strategic planning of its national infrastructure management and 
processing for the European Open Science Cloud (EOSC).
Significant synergies can been leveraged with the suggested 
sister Use Case for proteomics41. The metabolomics and proteom-
ics communities have been extensively interacting on the data 
standards and formats side, where metabolomics has been able 
to adapt and adopt work that has been started by the proteomics 
community. Based on these preparatory steps, our proposal to 
establish metabolomics as a Use Case in ELIXIR is a logical 
progression.
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The manuscript promotes a phenome-oriented view on metabolomics, with emphasis on bioinformatics of
known/identified compounds and permeating a systems biology view at the expense of the more explorative side of
untargeted approaches. This is understandable from the perspective of Elixir and PhenoMeNal, but somewhat
misrepresentative of the larger metabolomics community, which obviously hasn’t yet matured to the stages of
other (older) omics disciplines due to e.g. technical heterogeneity in platforms and difficulties in identification. On
the other hand, these potentially different perspectives converge in the emphasis on metabolite identification.
 
The manuscript is furthermore likely difficult to penetrate for those readers that may not be fully up to date on
European and international efforts for streamlining bioinformatics infrastructures. A more thorough introduction
would help lower that threshold.
 
More detailed comments:
The article pre-supposes knowledge from the reader on organisations, infrastuctures and current research political
agendas on European level, as well as what similar trajectories can be observed outside of Europe. A presentation
of past efforts in streamlining standards and needs for international organisations, as well as a more thorough
introduction on Elixir, PhenoMeNal and other initiatives would have been in order to help the less initiated reader
to follow the article. These background issues should be more thoroughly explained, broadened and put into
relevant context to reduce the feeling of this being an Elixir-internal lobbying paper. E.g.
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 Consider in relation to this aspect that: “The objective of the meeting was to identify the principal
challenges within this field and prioritise actions, in particular those within the scope and mission of
ELIXIR.” AND the article title: “The future of metabolomics in ELIXIR”
The authors state that: “ELIXIR coordinates bioinformatics resources across its member states and help
researchers to find, analyse, and exchange biological data. It is a distributed infrastructure with a single
Hub based in Hinxton, United Kingdom, and an increasing number of Nodes located throughout Europe.
As of July 2017, ELIXIR has 20 national Nodes, with European Bioinformatics Institute (EMBL-EBI;
co-located with the Hub), working as a separate Node.” This description, however, hardly describes Elixir
from a functional point of view.
Moreover, considering that: “This opinion article is a call for support for a new ELIXIR metabolomics Use
Case” there is surprisingly little information on the Elixir use cases in the background section. What are the
aims, objectives and functionalities of the use cases and how do they relate to the core challenges in the
metabolomics community? Overlaps between use cases and challenges are addressed later in the article, but
for something this important, this should have been addressed in the introduction. 
The challenges/bottlenecks in metabolomics have been expertly identified. However, these challenges are not
exclusive to Elixir, but represents challenges to the entire metabolomics community.
 
2. “Genome-based metabolic reconstruction databases: These databases are built based on genomeCorrection: 
annotation, mostly of enzymes and their association to known reactions, and thus may not cover the entire
metabolome since some  have no enzymatic function associated”genes that are enzymes
 
The section on current standards and techniques for multiOMICs integration is sketchy: “Currently, metabolomics
data can be integratively visualised with transcriptomics data.”. There are several interesting and promising
initiatives for data integration extending well beyond visual integration with transcriptomics as the authors are well
aware. There is, however, a lack of validated tools. Especially for supervised data analysis of integrated data (data
integration isn’t limited to systems biology through pathway analysis, but is also highly relevant from a
biostatistical point of view). But I also agree that there is “a lack of integrated omic databases”, although I believe
that there are several crucial aspects of data integration that need to be addressed well before we go into database
issues. The systems biology approach will furthermore not be advisable in an untargeted metabolomics setting:
Where complementarity in biological information from the different omics layers may be utilised for predictive
modelling of e.g. disease pathophysiology of risk modelling  compound identification (and may, in fact evenbefore
be used as a strategy  compound identification through e.g. Bayesian network modelling).for
 
Regarding metabolite identification, the authors state: “Concerted efforts in ELIXIR and the community…” The
order should probably be the inverse.
 
: “The Data Platform focuses on sustaining  life science data infrastructure”Correction long term Europe’s
 
A reflection on the “Data Platform” section is that many researchers seem to have perceived reporting formats for
the MetaboLights service as somewhat of a hurdle (as are most “general” issue added value tasks not
corresponding to the core task at hand for most funded research (e.g. identifying predictive biomarkers of a
specific disease). Whereas I have seen several BYOD initiatives for actual analysis of data, I still haven’t seen
BYOD approaches would metadata handling. Maybe these exist – From a user-friendliness perspective it would be
interesting to see how this hurdle is being tackled. It would also be interesting to have survey results on perceived
bottlenecks in metabolights (and similar repositories) if such exist, which could potentially focus efforts into FAIR
reporting.
Is the topic of the opinion article discussed accurately in the context of the current literature?
Yes
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 Are all factual statements correct and adequately supported by citations?
Yes
Are arguments sufficiently supported by evidence from the published literature?
Partly
Are the conclusions drawn balanced and justified on the basis of the presented arguments?
Partly
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  Charles F. Burant
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 Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
This article is a nice summary of a meeting of European scientists who have a range of interests in
metabolomics-based science.  The review provides a summary of the main areas that the investigators considered
critical to move move both the technological aspects of the work forward, with securing the identification of
'unknown' metabolites found in biological samples, as the primary need.  The group also identified various aspects
of data science, data science and bioinformatics as other high priority needs.
I found the review to be detailed, informative and well referenced. The review is unabashedly Eurocentric,
appropriately so given that it was generated with the goal of highlighing European efforts.  Thus, it sometimes
reads as an advert for ELIXIR, but that does not distract measurably from the fine recitation of the opinions of the
participants.  
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 I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an
acceptable scientific standard.
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